bluebird bio

bluebird bio, Duke collaborate on value-based payment framework for gene therapy

Tuesday, May 23, 2017

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participate in a consortium led by Duke University’s Robert J. Margolis, M.D., Center for Health Policy to develop a broadly-supported path for value-based payment reform models for gene therapies and other innovative treatments.

[Read More]

Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

bluebird bio hires Susanna High and Andrew Obenshain

Monday, December 5, 2016

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, has announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief operating officer and Andrew Obenshain was named senior vice president and head of Europe.

[Read More]

Halloran Consulting Group expands Regulatory and Development Team

Friday, November 4, 2016

Halloran Consulting Group, a national consultancy guiding life science companies to optimize development and performance, has announced the expansion of its regulatory and development team with the hiring of additional, highly specialized consultants, Iva Toudjarska, Ph.D., MBA, as principal consultant, Amanda Ceres, MS, as senior consultant and Keri Siggers, Ph.D., as consultant II. Earlier this year, Michelle Rose, Ph.D., was hired as principal consultant, to further enhance the company’s ability to deliver regulatory strategies and services.

[Read More]

bluebird bio completes NIH review, moved forward with trial against recommendation

Thursday, June 11, 2015

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, has completed the NIH Recombinant DNA Advisory Committee’s (RAC) public review of the HGB-208 pediatric study protocol for bluebird bio’s LentiGlobin BB305 product candidate in beta-thalassemia major. The RAC recommendation was to delay initiation of the study in the U.S. for one to two years. This recommendation has no effect on the HGB-207 protocol plan.

[Read More]